M&A - ACORN BIOVENTURES, L.P.

Form Type: SCHEDULE 13D/A

Filing Date: 2025-05-30

Corporate Action: Merger

Type: Update

Accession Number: 000163658725000030

Filing Summary: This filing by Acorn Bioventures, L.P. and its affiliates provides an update on their investment in OnKure Therapeutics, Inc. Following a merger completed on October 4, 2024, the predecessor company changed its name from Reneo Pharmaceuticals, Inc. to OnKure Therapeutics, with Legacy OnKure becoming a wholly owned subsidiary. Acorn reported acquiring additional shares of OnKure's common stock on May 15, 2025, totaling 1,399,000 shares at a purchase price of $1.85 per share, amounting to $2,590,000. The filing also elaborates on the Reporting Persons' intentions regarding potential future transactions involving the issuer's stock, emphasizing a strategy focused on investment without immediate plans for any significant corporate actions or structural changes within OnKure.

Form Type: SCHEDULE 13D

Filing Date: 2025-05-22

Corporate Action: Merger

Type: Update

Accession Number: 000163658725000027

Filing Summary: Acorn Bioventures, L.P. and its associated entities, including Acorn Capital Advisors GP, LLC and others, have reported their acquisition of shares in OnKure Therapeutics, Inc. following a merger that took place on October 4, 2024. The merger involved Radiate Merger Sub I, Inc. and Legacy OnKure, leading to OnKure changing its name from Reneo Pharmaceuticals, Inc. In this merger, Acorn received 1,439,674 shares of the common stock of OnKure. Recently, on May 15, 2025, Acorn and its affiliate Acorn 2 acquired an aggregate of 1,400,000 shares (270,270 and 1,129,730 shares, respectively) of OnKure's common stock at a price of $8.15 per share, totaling approximately $11.41 million. The entities involved intend to continue monitoring their investments and may explore various actions concerning their holdings, though they indicated no immediate changes to governance or structure of OnKure.